Two-year outcome of concurrent chemoradiation with carboplatin with or without adjuvant carboplatin/fluorouracil in nasopharyngeal cancer: A multicenter randomized trial

Chitapanarux, Imjai; Kittichest, Rungarun; Tungkasamit, Tharatorn; Asakit, Tussawan; Chomprasert, Kittisak; Chakrabandhu, Somvilai; Onchan, Wimrak; Traisathit, Patrinee

doi:10.1016/j.currproblcancer.2020.100620

Cited by 6 publications

(6 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Literature review and clinical interpretation Replacing cisplatin with carboplatin is also acceptable if cisplatin is contraindicated. 94,152 A single-center randomized, noninferiority trial compared the Intergroup regimen above to carboplatin infusion of 100 mg/m 2 concurrent with RT followed by carboplatin (AUC 5 intravenously) and 5fluorouracil (100 mg/m 2 /day over 96 hours) in 206 patients with NPC. Forty-two percent of patients in the cisplatin group completed the three cycles of AC compared with 73% in the carboplatin group.…”

Section: Clinical Questionmentioning

confidence: 99%

“…The same group also conducted a multicenter randomized trial to compare concurrent chemoradiation with carboplatin to the same regimen with adjuvant carboplatin and 5-fluorouracil in 175 patients with T2N0-T4N2M0 NPC (UICC/AJCC 7th edition). 152 The addition of adjuvant carboplatin-fluorouracil resulted in significantly improved 2-year disease-free survival. Literature review and clinical interpretation.…”

Section: Clinical Questionmentioning

confidence: 99%

See 1 more Smart Citation

Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline

Chen

Ismaila

Chua

et al. 2021

JCO

249

184

View full text Add to dashboard Cite

PURPOSE The aim of this joint guideline is to provide evidence-based recommendations to practicing physicians and other healthcare providers on definitive-intent chemoradiotherapy for patients with stage II-IVA nasopharyngeal carcinoma (NPC). METHODS The Chinese Society of Clinical Oncology (CSCO) and ASCO convened an expert panel of radiation oncology, medical oncology, surgery, and advocacy representatives. The literature search included systematic reviews, meta-analyses, and randomized controlled trials published from 1990 through 2020. Outcomes of interest included survival, distant and locoregional disease control, and quality of life. Expert panel members used this evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS The literature search identified 108 relevant studies to inform the evidence base for this guideline. Five overarching clinical questions were addressed, which included subquestions on radiotherapy (RT), chemotherapy sequence, and concurrent, induction, and adjuvant chemotherapy options. RECOMMENDATIONS Evidence-based recommendations were developed to address aspects of care related to chemotherapy in combination with RT for the definitive-intent treatment of stage II to IVA NPC. Additional information is available at www.asco.org/head-neck-cancer-guidelines .

show abstract

Section: Clinical Questionmentioning

confidence: 99%

Section: Clinical Questionmentioning

confidence: 99%

Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline

Chen

Ismaila

Chua

et al. 2021

JCO

249

184

View full text Add to dashboard Cite

show abstract

“…The rates of nephrotoxicity, leukopenia, and anemia in the cisplatin group were higher, while the rate of thrombocytopenia in the carboplatin group was higher [119]. The team also conducted a multicenter randomized trial that compared carboplatin concurrent chemoradiation with carboplatin concurrent chemoradiation plus carboplatin and 5-fluorouracil adjuvant chemotherapy in 175 patients with NPC (T2N0-T4N2M0) (UICC/AJCC seventh edition) [145]. The results showed that the addition of carboplatin and 5-fluorouracil adjuvant chemotherapy could significantly improve the patients' 2-year DFS.…”

Section: Notesmentioning

confidence: 99%

The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma

Tang¹,

Chen²,

Chen³

et al. 2021

Cancer Communications

210

140

View full text Add to dashboard Cite

Nasopharyngeal carcinoma (NPC) is a malignant epithelial tumor originating in the nasopharynx and has a high incidence in Southeast Asia and North Africa. To develop these comprehensive guidelines for the diagnosis and management of NPC, the Chinese Society of Clinical Oncology (CSCO) arranged a multi-disciplinary team comprising of experts from all sub-specialties of NPC to write, discuss, and revise the guidelines. Based on the findings of evidencebased medicine in China and abroad, domestic experts have iteratively developed these guidelines to provide proper management of NPC. Overall, the guidelines describe the screening, clinical and pathological diagnosis, staging and risk assessment, therapies, and follow-up of NPC, which aim to improve the management of NPC.

show abstract

“…We retrospectively obtained data from the entire group of stage II–IVA non-metastatic NPC patients who were treated in the CCRT and AC arms of the prospective cohort study conducted between 2015 and 2018 and enrolled among five cancer centers in Thailand [ 19 ]. In the prospective study, patients were stratified by center and randomized 1:1 into the CCRT arm or the CCRT + AC arm.…”

Section: Methodsmentioning

confidence: 99%

Longitudinal measurements of neutrophil-to-lymphocyte ratio in nasopharyngeal cancer treated with concurrent chemoradiotherapy

Muangwong,

Homkham,

Narueban

et al. 2023

PLoS ONE

Self Cite

View full text Add to dashboard Cite

Objective We study factors affecting neutrophil-to-lymphocyte ratio (NLR) and its changes throughout the treatment (ΔNLR) of nasopharyngeal carcinoma (NPC) underwent chemoradiotherapy (CCRT) followed by adjuvant chemotherapy (AC) and oncological outcomes including overall survival (OS) and disease-free survival (DFS). Methods Data from 81 NPC patients was retrospectively evaluated. NLRs were obtained from first week of CCRT (pre-CCRT), last week of CCRT (end-CCRT), and at last cycle of AC (end-AC). Pre-CCRT NLR was categorized into “low” and “high”. End-CCRT and end-AC ΔNLRs were divided into “increased” and “decreased” based on NLR at these two timepoints relative to the value at pre-CCRT. Associations between sex, age, cancer stage and NLR, ΔNLRs were investigated. OS and DFS were reported. Results Median NLR at pre-CCRT (2.47) was lower than NLR at end-CCRT (6.29) and end-AC (3.77) (P-value = 0.043). Advanced cancer stage associated with high pre-CCRT NLR (P-value = 0.047). Male gender was associated with "increased" end-CCRT ΔNLR, whereas male gender and age ≤51 were associated with "increased" end-AC ΔNLR. Three-year OS and DFS rates were 85.25% and 76.39%, respectively. There were no statistically significant differences observed in OS and DFS among groups categorized by pre-CCRT NLR, ΔNLRs, gender, age, and cancer stage. Conclusions NLR increases during NPC treatment. Advanced staging is associated with higher baseline NLR. Increased ΔNLR is associated with male gender at end-CCRT and male gender with age ≤51 years at end-AC. No relation between NLR and its dynamic change with either OS or DFS was demonstrated.

show abstract

Two-year outcome of concurrent chemoradiation with carboplatin with or without adjuvant carboplatin/fluorouracil in nasopharyngeal cancer: A multicenter randomized trial

Cited by 6 publications

References 19 publications

Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline

Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline

The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma

Longitudinal measurements of neutrophil-to-lymphocyte ratio in nasopharyngeal cancer treated with concurrent chemoradiotherapy

Contact Info

Product

Resources

About